← Back to Clinical Trials
Recruiting NCT06153888

NCT06153888 ULtrafiltration-Rate Induced CArdiac Strain (ULRICA) - Study

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06153888
Status Recruiting
Phase
Sponsor Umeå University
Condition Fluid Overload
Study Type INTERVENTIONAL
Enrollment 40 participants
Start Date 2023-03-20
Primary Completion 2026-03-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Ultrafiltration rate

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 40 participants in total. It began in 2023-03-20 with a primary completion date of 2026-03-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Patients performing chronic hemodialysis (HD) retain more or less water between dialyses. The water is removed by ultrafiltration and usually during the cleansing of waste products - the HD. The length of HD is usually the same as the time of fluid removal while sometimes this may differ. There is no clear guideline. In previous research the investigator noted that the heart releases more NT-pro-BNP during HD in numerous of the patients. The present study aims to clarify if the speed of fluid removal during HD is a factor that may alter the release of cardiac markers during HD. If so the recommendations for the prescription of HD can be updated.

Eligibility Criteria

Inclusion Criteria: * Adult HD patients with an intra-dialytic weight gain (IDWG) ≥2.5% of target weight over the long interval (3 days) prior to inclusion. * Patients need to be able to understand the study information * Patients need to be able to give consent. Exclusion Criteria: * Active systemic inflammatory state such as extensive malignancy or acute septic infection. * Uncontrolled hyperphosphatemia decided by the local routine of the physician (due to somewhat decreased efficacy of the low flux filter to eliminate phosphate)

Contact & Investigator

Central Contact

Bernd Stegmayr, MD, PhD

✉ bernd.stegmayr@umu.se

📞 +46706264533

Principal Investigator

Bernd Stegmayr, MD, PhD

PRINCIPAL INVESTIGATOR

Umea University, Umea, Sweden

Frequently Asked Questions

Who can join the NCT06153888 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Fluid Overload. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06153888 currently recruiting?

Yes, NCT06153888 is actively recruiting participants. Contact the research team at bernd.stegmayr@umu.se for enrollment information.

Where is the NCT06153888 trial being conducted?

This trial is being conducted at Umeå, Sweden.

Who is sponsoring the NCT06153888 clinical trial?

NCT06153888 is sponsored by Umeå University. The principal investigator is Bernd Stegmayr, MD, PhD at Umea University, Umea, Sweden. The trial plans to enroll 40 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology